Awards are an honor, but they are not why we do what we do. That's why this year's recognition from the APEX Awards is especially meaningful. BioWorld earned seven 2026 APEX Awards, including three Grand Awards and four Awards of Excellence. Judged by publishing industry peers, these honors recognize excellence across reporting, writing, visual storytelling and editorial collaboration. While we are proud of this recognition, what makes it especially rewarding is that it reflects the work our team does every day to serve the global life sciences community.
Jiangxi Kerui Pharmaceutical Co. Ltd. has disclosed new prodrugs of fungal GPI-anchored wall transfer protein 1 (GWT1) inhibitors potentially useful for the treatment of fungal infections.
Changchun Genescience Pharmaceuticals Co. Ltd. has synthesized new molecular glue degraders comprising E3 ubiquitin-protein ligase-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are described as potentially useful for the treatment of ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis.
Genescience Pharmaceuticals Co. Ltd. has been developing an SLC6A19 inhibitor – Gensci-144 – for the potential treatment of chronic kidney disease (CKD).
Prostate cancer is a leading cause of cancer-related deaths among men and is a cancer type that shows genomic heterogeneity and several molecular alterations. By analyzing available microarray and next-generation transcriptome sequencing data, researchers at the University of Alabama at Birmingham found that thyroid hormone receptor-interacting protein 13 (TRIP13), a member of the AAA ATPase family, was overexpressed in prostate cancer, making it a potential therapeutic target.
Neurodegenerative disorders such as Alzheimer’s disease (AD) and frontotemporal dementia are characterized by the accumulation of hyperphosphorylated tau protein, forming neurofibrillary tangles, ultimately leading to synaptic dysfunction and cognitive decline.
Chronic activation or upregulation of interleukin-1 receptor-associated kinase 4 (IRAK4) has been linked to several diseases, including systemic lupus erythematosus, rheumatoid arthritis, atopic dermatitis, Alzheimer’s disease and atherosclerosis. Researchers from the Ocean University of China aimed to address the limitations of traditional small-molecule inhibitors by designing novel proteolysis targeting chimeras (PROTACs) for IRAK4 degradation.
RSS
